Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-27 @ 12:39 PM
Study NCT ID:
NCT05755360
Status:
COMPLETED
Last Update Posted:
2025-10-02
First Post:
2023-02-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
Sponsor:
Novo Nordisk A/S
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-02-21
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-21
Completion Date Type:
ACTUAL
First Submit Date:
2023-02-23
First Submit QC Date:
None
Study First Post Date:
2023-03-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-01
Last Update Post Date:
2025-10-02
Last Update Post Date Type:
ESTIMATED